Izrael - héber - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 0.25 mg - everolimus - everolimus - kidney and heart transplantationcertican ® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

Izrael - héber - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - héber - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - héber - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Izrael - héber - Ministry of Health

novartis israel ltd - fingolimod as hydrochloride - קפסולה קשיחה - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disabiliry.

Izrael - héber - Ministry of Health

novartis israel ltd - diclofenac as potassium - טבליה - diclofenac as potassium 50 mg - diclofenac - diclofenac - management of pain and primary dysmenorrhea, when prompt pain relief is desired.

Izrael - héber - Ministry of Health

novartis israel ltd - baclofen - טבליה - baclofen 10 mg - baclofen - baclofen - muscle spasticity of various origins.

Izrael - héber - Ministry of Health

novartis israel ltd - zoledronic acid - תמיסה לאינפוזיה - zoledronic acid 5 mg / 100 ml - zoledronic acid - zoledronic acid - treatment of paget's disease of the bone. treatment of osteoporosis : - in post-menopausal women - in men at increased risk of fracture including those with a recent low-trauma hip fracture.treatment and prevention of glucocorticoid-induced osteoporosis.prevention of postmenopausal osteoporosis in women for whom bisphosphonate therapy is indicated.

Izrael - héber - Ministry of Health

novartis israel ltd - carbamazepine - טבליה - carbamazepine 200 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic depressive illness.

Izrael - héber - Ministry of Health

novartis israel ltd - carbamazepine - טבליות בשחרור איטי - carbamazepine 400 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in mania depressive illness.